ANAPTYSBIO, INC. Form 10-K: Annual report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-03-03: Form 10-K; Period of report 2025-12-31; Description 10-K; Document anab-20251231.htm.
- 2025-02-27: Form 10-K; Period of report 2024-12-31; Description 10-K; Document anab-20241231.htm.
- 2024-03-11: Form 10-K; Period of report 2023-12-31; Description 10-K; Document anab-20231231.htm.
- 2023-03-01: Form 10-K; Period of report 2022-12-31; Description 10-K; Document anab-20221231.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-03-03 | 10-K | 2025-12-31 | 10-K | anab-20251231.htm |
| 2025-02-27 | 10-K | 2024-12-31 | 10-K | anab-20241231.htm |
| 2024-03-11 | 10-K | 2023-12-31 | 10-K | anab-20231231.htm |
| 2023-03-01 | 10-K | 2022-12-31 | 10-K | anab-20221231.htm |
| 2022-03-07 | 10-K | 2021-12-31 | 10-K | anab-20211231.htm |
| 2021-02-25 | 10-K | 2020-12-31 | 10-K | anab-20201231.htm |
| 2020-03-02 | 10-K | 2019-12-31 | 10-K | anab-12311910k.htm |
| 2019-02-28 | 10-K | 2018-12-31 | 10-K | anab-12311810k.htm |
| 2018-03-05 | 10-K | 2017-12-31 | 10-K | anab-123117x10k.htm |
| 2017-03-08 | 10-K | 2016-12-31 | 10-K | anab-10k_20161231.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |